Clinical trials
Active, not recruiting Urinary Bladder Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
142 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2003 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 6 |
| 2017 | 8 |
| 2018 | 11 |
| 2019 | 16 |
| 2020 | 16 |
| 2021 | 19 |
| 2022 | 16 |
| 2023 | 13 |
| 2024 | 14 |
| 2025 | 7 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Active, not recruiting | 142 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 13 |
| Memorial Sloan Kettering Cancer Center | 9 |
| M.D. Anderson Cancer Center | 8 |
| AstraZeneca | 5 |
| Jonsson Comprehensive Cancer Center | 4 |
| Merck Sharp & Dohme LLC | 4 |
| BicycleTx Limited | 3 |
| Janssen Research & Development, LLC | 3 |
| Cedars-Sinai Medical Center | 2 |
| Fox Chase Cancer Center | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Urinary Bladder Neoplasms | 142 |
| Carcinoma, Transitional Cell | 35 |
| Ovarian Neoplasms | 19 |
| Prostatic Neoplasms | 17 |
| Non-Muscle Invasive Bladder Neoplasms | 16 |
| Carcinoma, Non-Small-Cell Lung | 12 |
| Carcinoma, Renal Cell | 12 |
| Lung Neoplasms | 12 |
| Stomach Neoplasms | 12 |
| Triple Negative Breast Neoplasms | 12 |
Trials
Showing 1 to 25 of 142. Each trial links to its page on Pharma Observatory.
42 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.